MedicalDevice Licensing.com
Pharmalicensing.com
Latest: Watch here for details of new products and services.
RSS Feeds
Advanced search

Login  Register

About Us
Pharmalicensing - Partnering solutions for the life sciences
 
Our Products
Overview
Partnering Search
Company Profiling
Deal Negotiation
PL Intelligence
Reports
Comparison
 
PL Intelligence
Overview
Industry news
Deals review
Press releases
Articles
 
Case Studies
See what others think about our service
 
Newsletter
Partnering update
Key reports
Subscribe
 
Quick Links
Profile now
Register now
Profiled companies
Featured events
Industry news
PR Newswire
Jobs
Forums
 
Contact Pharmalicensing
Send an email
Call us: +44 1904 520460
Request a callback
 
RSS Feeds
Keep up to date

Pharmalicensing
is a division of
UTEK Europe Ltd
UTEK Corporation
Industry news

News of the day

Amylin Pharmaceuticals and Takeda Enter into Worldwide Agreement to Co-Develop and Commercialize Compounds for Obesity

San Diego, CA - November 1, 2009 and Osaka, Japan - November 2, 2009 - Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Takeda Pharmaceutical Company Limited (TSE: 4502) announced today that they have entered into a worldwide exclusive license, development and commercialization agreement to co-develop and commercialize pharmaceutical products for the treatment of obesity and related indications. more

Echo Therapeutics Announces Significant Advance in Development of its One-Piece, Needle Free Symphony tCGM Biosensor

FRANKLIN, Mass., October 29, 2009 -- Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a diabetes management company developing the needle-free Symphony(TM) tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude(TM) SkinPrep System for transdermal drug delivery, announced today that it has made significant advances to the development of its needle-free Symphony tCGM biosensor. The biosensor replaces the prototype two-piece biosensor... more

Norgine acquires cetilistat

October 26, 2009 -- Norgine BV today announced that it has purchased cetilistat, a novel treatment for obesity from Alizyme Therapeutics Limited. Norgine has acquired global rights to the product, including an assignment of the existing partnering arrangement with Takeda for a cash payment and a share of certain future revenues. more

Industry news search

Search the Pharmalicensing Industry news by keyword. Alternatively our advanced search allows you to query by category and therapeutic target.
 
Category Therapeutic target
 
To choose more then one item on the list hold CTRL button while selecting. To deselect items press CTRL button and deselect.

Recent news

To keep up to date with news from this category use our RSS Feed to keep up to date

Sanofi-aventis and Wellstat Therapeutics enter into an Exclusive Worldwide Licensing Agreement for novel oral agent to treat Type II Diabetes
Paris, France - October 21, 2009 - Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and Wellstat Therapeutics Corporation announced today a global licensing agreement on PN2034, a novel oral first-in-class, insulin...

Tolerx Presents Otelixizumab Phase 2 Dose Optimization Data at the IDF's 20TH World Diabetes Congress
MONTREAL, CANADA - October 21, 2009 - Tolerx, Inc., a biopharmaceutical company developing novel therapies intended to treat diabetes, other autoimmune diseases and cancer by specifically modulating T-cell activity,...

Shire Targets Fourth Quarter Filing of BLA for REPLAGAL
Massachusetts - 21 Oct 2009 - Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces plans to file a Biologics License Application (BLA) with the U.S. Food and Drug Administration...

Galapagos expands strategic alliance in metabolic disease with Merck & Co., Inc
Mechelen, Belgium 14 October 2009 - Galapagos NV (Euronext: GLPG) announced today that it has expanded its global strategic alliance in metabolic diseases with an affiliate of Merck & Co., Inc to incorporate the...

Data on VIVUS' Qnexa To Be Featured at The Obesity Society Annual Meeting
MOUNTAIN VIEW, Calif., Oct 05, 2009 -- VIVUS,Inc. (Nasdaq: VVUS) today announced that data on Qnexa(TM), an investigational new drug, will be presented at the 27th annual scientific meeting of The Obesity Society (TOS)...

Boehringer Ingelheim`s diabetes pipeline continues to advance as the Company announces conclusion of robust Phase III pivotal trials programme for linagliptin
Ingelheim/Germany, 28 September 2009 - Following the release of linagliptin Phase II data earlier this year, Boehringer Ingelheim has now announced the conclusion of the linagliptin pivotal Phase III clinical trials....

Arena Pharmaceuticals Reports Positive, Highly Significant BLOSSOM Trial Results for Weight Management; NDA Submission on Track for December
SAN DIEGO, Sept 18, 2009 -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) reported today positive, highly significant top-line results from the BLOSSOM (Behavioral modification and LOrcaserin Second Study for Obesity...

ConjuChem Announces Fiscal 2009 Third Quarter Financial Results
MONTREAL, Canada, September 14, 2009 - ConjuChem Biotechnologies (TSX:CJB) today announced financial results for the third quarter of fiscal 2009, ended July 31, 2009. "During our fiscal third quarter, we had the...

Aegis Therapeutics and Albany Medical College Expand Collaboration for Novel Oral Anti-Obesity Drug
SAN DIEGO, CA August 26, 2009 - Aegis Therapeutics and Albany Medical College announced today that they have expanded their existing research relationship, entering into a joint commercialization agreement to promote...

Clients in focus...

Get the Flash Player to see this rotator.

Partnering discussion free of charge
Biobusiness 2009
Need competitive intelligence information
Press releases: Pharmalicensing current industry press releases.

© Copyright 1995-2009 Pharmalicensing, a division of UTEK Europe Ltd UTEK Corporation All rights reserved. Terms and Conditions | Contact us